文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

人工胰腺治疗门诊1型糖尿病患者的系统评价与Meta分析

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2018-04-18

该研究系统评价和Meta分析了40项随机对照试验(1027名参与者,44项比较),评估人工胰腺系统对非妊娠门诊1型糖尿病患者的疗效与安全性。结果显示,人工胰腺系统显著提高传感器血糖处于近正常范围(3.9-10 mmol/L)的时间比例,且不增加低血糖风险。结论认为人工胰腺系统是有效且安全的治疗方式,但现有证据存在结局报告不一致、样本量小和随访时间短等局限。

要点

  • 人工胰腺系统显著增加门诊1型糖尿病患者血糖处于3.9-10 mmol/L的时间比例。
  • 该系统不增加低血糖风险,且降低高血糖时间比例。
  • 证据局限性包括结局报告不一致、样本量小和随访时间短。

核心结论

  • 人工胰腺系统是治疗门诊1型糖尿病患者的有效且安全的方法。

研究设计与样本

  • 系统评价与Meta分析,纳入随机对照试验,数据来源包括Medline、Embase、Cochrane Library和灰色文献至2018年2月2日。
  • 共纳入40项研究(1027名参与者,44项比较),其中35项比较评估单激素人工胰腺系统,9项比较评估双激素系统。
  • 仅9项研究为低偏倚风险。

主要发现

  • 人工胰腺系统组过夜传感器血糖在近正常范围(3.9-10.0 mmol/L)的时间比例显著更高(加权均数差15.15%,95%CI 12.21%至18.09%)。
  • 24小时内传感器血糖在近正常范围的时间比例显著更高(9.62%,95%CI 7.54%至11.7%)。
  • 24小时内传感器血糖高于10 mmol/L的时间比例显著降低(-8.52%,95%CI -11.14%至-5.9%)。
  • 24小时内传感器血糖低于3.9 mmol/L的时间比例显著降低(-1.49%,95%CI -1.86%至-1.11%)。
  • 敏感性分析仅纳入低偏倚风险试验(11.64%,95%CI 9.1%至14.18%)或无人监督正常生活条件下的试验(10.42%,95%CI 8.63%至12.2%),主要结局结果稳健。

关键数值与推荐

  • 主要结局为传感器血糖处于近正常范围(3.9-10 mmol/L)的时间百分比。
  • 次要结局包括传感器血糖高于10 mmol/L或低于3.9 mmol/L的时间百分比、夜间低血糖指数、平均传感器血糖、每日总胰岛素需求和糖化血红蛋白。

临床怎么用

  • 人工胰腺系统可用于门诊1型糖尿病患者的血糖管理,尤其有助于增加目标范围内时间并减少高低血糖波动。

局限性

  • 现有研究证据的主要局限性包括结局报告不一致、样本量小和单个试验随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of artificial pancreas treatment in non-pregnant outpatients with type 1 diabetes. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, Cochrane Library, and grey literature up to 2 February 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials in non-pregnant outpatients with type 1 diabetes that compared the use of any artificial pancreas system with any type of insulin based treatment. Primary outcome was proportion (%) of time that sensor glucose level was within the near normoglycaemic range (3.9-10 mmol/L). Secondary outcomes included proportion (%) of time that sensor glucose level was above 10 mmol/L or below 3.9 mmol/L, low blood glucose index overnight, mean sensor glucose level, total daily insulin needs, and glycated haemoglobin. The Cochrane Collaboration risk of bias tool was used to assess study quality. RESULTS: 40 studies (1027 participants with data for 44 comparisons) were included in the meta-analysis. 35 comparisons assessed a single hormone artificial pancreas system, whereas nine comparisons assessed a dual hormone system. Only nine studies were at low risk of bias. Proportion of time in the near normoglycaemic range (3.9-10.0 mmol/L) was significantly higher with artificial pancreas use, both overnight (weighted mean difference 15.15%, 95% confidence interval 12.21% to 18.09%) and over a 24 hour period (9.62%, 7.54% to 11.7%). Artificial pancreas systems had a favourable effect on the proportion of time with sensor glucose level above 10 mmol/L (-8.52%, -11.14% to -5.9%) or below 3.9 mmol/L (-1.49%, -1.86% to -1.11%) over 24 hours, compared with control treatment. Robustness of findings for the primary outcome was verified in sensitivity analyses, by including only trials at low risk of bias (11.64%, 9.1% to 14.18%) or trials under unsupervised, normal living conditions (10.42%, 8.63% to 12.2%). Results were consistent in a subgroup analysis both for single hormone and dual hormone artificial pancreas systems. CONCLUSIONS: Artificial pancreas systems are an efficacious and safe approach for treating outpatients with type 1 diabetes. The main limitations of current research evidence on artificial pancreas systems are related to inconsistency in outcome reporting, small sample size, and short follow-up duration of individual trials.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018. PMID: 29669716. doi:10.1136/bmj.k1310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。